STOCK TITAN
  1. Home
  2. News
  3. KYMR

Kymera Therapeutics, Inc. - KYMR STOCK NEWS

Welcome to our dedicated page for Kymera Therapeutics news (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics stock.

Kymera Therapeutics, Inc. (NASDAQ: KYMR) is a biotechnology company harnessing the power of targeted protein degradation (TPD) to develop transformative treatments for previously untreatable diseases. Founded in 2016, and headquartered in Watertown, Massachusetts, Kymera is at the forefront of biotechnology, utilizing the body's innate protein recycling machinery to degrade disease-causing proteins rather than merely inhibiting them.

The company's pioneering platform, Pegasus™, leverages proprietary predictive modeling and an integrated degradation approach to address disease targets previously deemed intractable. This novel modality allows Kymera to target and degrade proteins involved in various critical pathways, including those in immunological diseases and oncology. Key drugs in their pipeline include:

  • KT-474: An IRAK4 degrader currently in Phase 2 trials for immuno-inflammatory conditions.
  • KT-333: A STAT3 degrader in Phase 1 trials, targeting hematological malignancies and solid tumors.
  • KT-253: An MDM2 degrader undergoing Phase 1 trials, aimed at cancers with p53 pathway involvement.
  • KT-621: A STAT6 degrader poised to enter Phase 1 trials, showing promising preclinical results for treating TH2-driven diseases like asthma and atopic dermatitis.

Kymera's achievements include successful partnerships with leading pharmaceutical companies such as Sanofi, ongoing collaborations with research institutions, and securing significant financial backing with over $745 million in cash reserves to support operations into 2027. The company's innovative approach and robust pipeline have earned it recognition as one of Boston’s top workplaces.

Kymera continues to make significant strides in drug discovery and development, with a focus on delivering highly effective, convenient oral therapies. Recent updates include positive preclinical and clinical data presentations at major medical conferences, highlighting the potential of their degradation technology to revolutionize treatment paradigms across various diseases.

For more information, visit Kymera Therapeutics or follow them on X (formerly Twitter) and LinkedIn.

News

Kymera Therapeutics to Present in Fireside Chat at the Guggenheim Healthcare Conference

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference in New York, NY on February 7, 2024, at 9:30 a.m. ET. The company is a clinical-stage biopharmaceutical company focusing on small molecule medicines using targeted protein degradation (TPD). A live webcast of the fireside chat will be available on the company's website, with a replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
conferences
-
News

Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced its corporate goals for 2024, including anticipated progress on its best-in-class pipeline of immunology and oncology programs. The company has well-capitalized, with cash in excess of $745 million and expected runway into the first half of 2027.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
none
-
News

Kymera Therapeutics Announces Closing of Upsized $275 Million Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the closing of its upsized underwritten public offering of $275 million of shares of its common stock, raising approximately $316.2 million. Morgan Stanley, J.P. Morgan, TD Cowen, and UBS Investment Bank acted as joint lead bookrunning managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.8%
Tags
offering
News

Kymera Therapeutics Announces Pricing of $275 Million Public Offering

Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), announced the pricing of its underwritten public offering of $275 million of shares of its common stock and pre-funded warrants to purchase shares of its common stock. The offering is expected to close on January 9, 2024, and the company intends to use the net proceeds for advancing its pipeline of preclinical and clinical degrader programs, working capital, and other general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
offering
-
News

Kymera Therapeutics Announces Proposed Public Offering

Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), has announced a public offering of $250.0 million of shares of its common stock and warrants to purchase shares. The company plans to use the net proceeds to advance its pipeline of preclinical and clinical degrader programs, address large patient populations, and for working capital and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.15%
Tags
offering
-
News

R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) to advance first-in-class oral degraders with biologics-like activity targeting STAT6, TYK2, and IRAK4. KT-621 expected to enter Phase 1 clinical trial in 2H 2024, KT-294 in 1H 2025, and KT-474 to complete enrollment in both Phase 2 HS and AD studies in 4Q 2024, with topline data expected in 1H 2025. Company to hold virtual Immunology R&D Day webcast on Jan 4, 2024, to share overview of strategy and new programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.86%
Tags
acquisition
News

Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Founder, President, and CEO Nello Mainolfi, Ph.D., will provide an overview of the Company's progress and anticipated milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
News

Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will host a virtual Immunology R&D Day on January 4, 2024, to provide an update on its emerging pipeline of high-value immunology programs, new target disclosures, preclinical data, and clinical study initiation timing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
conferences
-
News

Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), shared new data from its ongoing KT-333 Phase 1 trial. KT-333, a first-in-class STAT3 degrader, demonstrated early signs of antitumor activity across liquid and solid tumors, with major responses in cutaneous T-cell lymphoma and Hodgkin's lymphoma. The drug was well-tolerated, showing robust STAT3 knockdown and positive immunomodulatory effects. The Phase 1 trial is evaluating the safety, tolerability, and clinical activity of KT-333 in adult patients with relapsed and/or refractory lymphomas, leukemias, and solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
clinical trial
News

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced the initiation of the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in Atopic Dermatitis (AD), generating a $15 million milestone payment under its collaboration with Sanofi. The trial is projected to be completed in the first quarter of 2025, with topline Phase 2 data from both the AD and Hidradenitis Suppurativa (HS) trials expected in the first half of 2025. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, generating a $40 million milestone payment under the terms of the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
clinical trial

FAQ

What is the current stock price of Kymera Therapeutics (KYMR)?

The current stock price of Kymera Therapeutics (KYMR) is $40.66 as of December 20, 2024.

What is the market cap of Kymera Therapeutics (KYMR)?

The market cap of Kymera Therapeutics (KYMR) is approximately 2.5B.

What is Kymera Therapeutics' main focus?

Kymera Therapeutics focuses on developing treatments for previously untreatable diseases using targeted protein degradation to eliminate disease-causing proteins.

What is the Pegasus platform?

Pegasus is Kymera's proprietary platform that leverages predictive modeling and integrated degradation technologies to target and degrade intractable disease-causing proteins.

What are some key drugs in Kymera's pipeline?

Key drugs include KT-474 (IRAK4 degrader), KT-333 (STAT3 degrader), KT-253 (MDM2 degrader), and KT-621 (STAT6 degrader).

What diseases is Kymera targeting?

Kymera is targeting a range of diseases including immuno-inflammatory conditions, various forms of cancer, and TH2-mediated diseases like asthma.

What recent achievements has Kymera made?

Recent achievements include positive preclinical and clinical data, significant partnerships, and financial backing to support operations into 2027.

How does Kymera's technology differ from conventional therapies?

Kymera's technology degrades disease-causing proteins rather than merely inhibiting them, offering potentially more effective and lasting treatments.

Who are Kymera's partners?

Kymera has partnered with leading pharmaceutical companies such as Sanofi and collaborates with various research institutions.

Where is Kymera Therapeutics headquartered?

Kymera Therapeutics is headquartered in Watertown, Massachusetts.

How is Kymera funded?

Kymera has over $745 million in cash reserves, supporting operations and research efforts through various financial backings and a recent equity offering.

Where can I find more information about Kymera?

More information can be found on Kymera's website (www.kymeratx.com) and their official social media profiles on X (formerly Twitter) and LinkedIn.

Stock KYMR logo
Kymera Therapeutics, Inc.

Nasdaq:KYMR

KYMR Rankings

#1784 Ranked by Market Cap
N/A Ranked by Dividends

KYMR Stock Data

2.54B
63.89M
1.27%
108.43%
14.09%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
WATERTOWN